Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
You may also be interested in...
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
In another clear signal that China's innovative drug R&D is coming of age, most global rights to I-Mab's promising early-stage CD47 antibody have been picked up by AbbVie in a deal valued at close to $2bn.
Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.